Clinical-stage biotechnology company developing engineered, extended half-life antibody therapies and rational combination treatments for inflammatory bowel disease and other immune-mediated diseases
Clinical-stage biotechnology company developing engineered, extended half-life antibody therapies and rational combination treatments for inflammatory bowel disease and other immune-mediated diseases. Its investigational pipeline targets α4β7, TL1A, IL-23, and IL-17A/F.